Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib

American Journal of Ophthalmology

Volumn 158, Issue 4, 2014, Pages 831-837.e2

  Choe, Christina H ^e   McArthur, Grant A ^b   Caro, Ivor ^c   Kempen, John H ^a,d   Amaravadi, Ravi K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Carolina Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CORTICOSTEROID; CYCLOPLEGIC AGENT; DACARBAZINE; VEMURAFENIB; ALKYLATING AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLEPHARITIS; BLURRED VISION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL PHARMACOLOGY; CONJUNCTIVITIS; CUTANEOUS MELANOMA; DIPLOPIA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY EYE; EPISCLERITIS; EYE DISCOMFORT; EYE EDEMA; EYE TOXICITY; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPEREMIA; KERATITIS; KERATOACANTHOMA; LACRIMAL FLUID; LACRIMAL GLAND DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRIORITY JOURNAL; RASH; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; UVEITIS; VITREOUS FLOATERS; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; EYE DISEASE; GENETICS; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SKIN TUMOR; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CONJUNCTIVITIS; DACARBAZINE; DRY EYE SYNDROMES; EYE DISEASES; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; UVEITIS; YOUNG ADULT;

EID: 84908553757     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.07.003     Document Type: Article

References (24)

1. Martinez SR, Tseng WH, Young SE. Outcomes for lymph node-positive cutaneous melanoma over two decades. World J Surg 2011;35(7):1567-1572.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-954.
3. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239-1246.
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9):809-819.
5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707-714.
6. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26): 2507-2516.
7. Heakal Y, KesterM, Savage S. Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 2011;45(11):1399-1405.
8. Zografos L, Ducrey N, Beati D, et al. Metastatic melanoma in the eye and orbit. Ophthalmology 2003;110(11):2245-2256.
9. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18(5):1386-1394.
10. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365(25):2439-2441.
11. Aisenbrey S, Lüke C, Ayertey HD, Grisanti S, Perniok A, Brunner R. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: An 11-year follow-up. Graefes Arch Clin Exp Ophthalmol 2003;241(12):996-999.
12. Sober AJ, Haynes HA. Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 1978;114(3):439-441.
13. Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009;116(5):981-989.
14. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70(13): 5213-5219.
15. Huang W, Yang AH, Matsumoto D, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009;25(6):519-530.
16. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-2146.
17. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(8):2450-2457.
18. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-435.
19. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287): 427-430.
20. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-221.
21. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365(15): 1448-1449.
22. Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012;10(7):475-486.
23. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37(5):499-507.
24. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother 2004;27(6):478-479.